Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
CA14161Y2006
Fri, 14.06.2024
Cardiol Therapeutics Inc
First Berlin Equity Research has published a research update on Cardiol
Therapeutics Inc. (ISIN: CA14161Y2006). Analyst Christian Orquera
reiterated his BUY rating and increased the price target from USD 3.60 to
USD 8.50.
Abstract:
Cardiol Therapeutics (Cardiol) announced excellent topline data for its
phase II open-label pilot US study (MAvERI [ … ]
Tue, 27.02.2024
Cardiol Therapeutics Inc
First Berlin Equity Research has published a research update on Cardiol
Therapeutics Inc. (ISIN: CA14161Y2006). Analyst Christian Orquera
reiterated his BUY rating and maintained his USD 3.60 price target.
Abstract:
Cardiol Therapeutics (Cardiol) announced that the FDA has granted Orphan
Drug Designation (ODD) in the US for its lead drug candid [ … ]
Fri, 19.01.2024
Cardiol Therapeutics Inc
First Berlin Equity Research has published a research update on Cardiol
Therapeutics Inc. (ISIN: CA14161Y2006). Analyst Christian Orquera
reiterated his BUY rating and maintained his USD 3.60 price target.
Abstract:
Cardiol Therapeutics (Cardiol) has completed >50% of patient recruitment
for CardiolRx's two lead indications, acute myocarditi [ … ]
Wed, 30.08.2023
Cardiol Therapeutics Inc
First Berlin Equity Research has published a research update on Cardiol
Therapeutics Inc. (ISIN: CA14161Y2006). Analyst Christian Orquera
reiterated his BUY rating and maintained his USD 3.60 price target.
Abstract:
Cardiol Therapeutics has published its H1 2023 financial report. Overall
figures were in line with our expectations. The company r [ … ]
Wed, 24.05.2023
Cardiol Therapeutics Inc
First Berlin Equity Research has published a research update on Cardiol
Therapeutics Inc. (ISIN: CA14161Y2006). Analyst Christian Orquera
reiterated his BUY rating and maintained his USD 3.60 price target.
Abstract:
Cardiol Therapeutics has published its Q1/23 financial report and business
update, which was roughly in line with our expectations. [ … ]
Wed, 24.05.2023
Cardiol Therapeutics Inc
First Berlin Equity Research has published a research update on Cardiol
Therapeutics Inc. (ISIN: CA14161Y2006). Analyst Christian Orquera
reiterated his BUY rating and maintained his USD 3.60 price target.
Abstract:
Cardiol Therapeutics has published its Q1/23 financial report and business
update, which was roughly in line with our expectations. [ … ]
Tue, 11.04.2023
Cardiol Therapeutics Inc
First Berlin Equity Research hat die Coverage von Cardiol Therapeutics Inc
(ISIN: CA14161Y2006) aufgenommen. Das Rating von Analyst Christian Orquera
ist BUY bei einem Kursziel von USD 3,60 (€3,30).
Zusammenfassung:
Cardiol Therapeutics Inc. (Cardiol) ist ein Biotech-Unternehmen mit einer
Produktpipeline im klinischen Stadium, die sich auf [ … ]
Tue, 11.04.2023
Cardiol Therapeutics Inc
First Berlin Equity Research hat die Coverage von Cardiol Therapeutics Inc
(ISIN: CA14161Y2006) aufgenommen. Das Rating von Analyst Christian Orquera
ist BUY bei einem Kursziel von USD 3,60 (€3,30).
Zusammenfassung:
Cardiol Therapeutics Inc. (Cardiol) ist ein Biotech-Unternehmen mit einer
Produktpipeline im klinischen Stadium, die sich auf [ … ]
Fri, 16.12.2022
Cardiol Therapeutics
Contact DetailsProactive CanadaProactive Canada+1 604-688-8158na-editorial@proactiveinvestors.comNews Source: News Direct
16.12.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
Fri, 16.12.2022
Cardiol Therapeutics
Contact DetailsProactive CanadaProactive Canada+1 604-688-8158na-editorial@proactiveinvestors.comNews Source: News Direct
16.12.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.